Abstract

Implantable cardioverter-defibrillators (ICDs) have become a cornerstone in the management of patients at high risk for sudden cardiac death (SCD) due to life-threatening arrhythmias. As advancements in cardiac electrophysiology continue to evolve, the role of ICDs has expanded beyond mere defibrillation to encompass complex arrhythmia management and heart failure therapy. This article explores the clinical indications, technological advancements, and impact of ICDs on patient outcomes in the field of cardiac electrophysiology, highlighting their significance in both primary and secondary prevention of SCD.